Metastasis is the main cause of mortality in breast cancer patients. CD82, a metastasis suppressor has been shown to be lowly expressed in metastatic breast cancer. This review by Prof Bay Boon Huat and his team proposes targeting CD82 as a therapeutic approach to hinder metastases in breast cancer patients. The main goal of targeting CD82 as an innovative therapeutic approach is to prevent cancer spread by an appropriate selection of non-metastatic breast cancer patients with low CD82 expression and restoring the CD82 levels with either clinically approved drugs, CD82 peptide mimics or non-coding RNA-based therapeutics.
The study was published in scientific journal, Cancers, in September 2021.
Read more on the study here https://www.mdpi.com/1259658
